BridgeBio Pharma
Biopharmaceutical company developing transformative medicines for patients with genetic diseases and cancers.
About
BridgeBio is a biopharmaceutical company focused on bringing meaningful medicines to patients quickly and safely. They develop and deliver treatments for genetic diseases, with a pipeline that includes approved medicines like Attruby® (acoramidis) and NULIBRY® (fosdenopterin), as well as investigational therapies for conditions such as Transthyretin Amyloidosis and Limb-Girdle Muscular Dystrophy. BridgeBio serves patients by advancing a diverse pipeline of therapeutic candidates from discovery through to commercialization. Teams look it up for Biotech, Pharmaceuticals, Healthcare.
Frequently asked
What does BridgeBio Pharma do?
BridgeBio Pharma is a Biotech company that offers Services. Teams look it up for Pharmaceuticals, Healthcare. It is based in Palo Alto, United States and was founded in 2015. Public records show about 875 people. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, United States.
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
What industry does BridgeBio Pharma operate in?
BridgeBio Pharma operates in Biotech, Pharmaceuticals, Healthcare.
How many employees does BridgeBio Pharma have?
BridgeBio Pharma has approximately 875 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.